OBJECTIVE: To screen commonly used prescription drugs for possible carcinogenic effects. METHODS: In a large health care program we identified 105 commonly used drugs, not previously screened. Recipients were followed for up to 12½ years for incident cancer. Nested case-control analyses of 55 cancer sites and all combined included up to ten matched controls per case, with lag of at least 2 years between drug dispensing and cancer. Positive associations entailed a relative risk of 1.50, with p ≤ 0.01 and higher risk for three or more, than for one prescription. Evaluation included further analyses, searches of the literature, and clinical judgment. RESULTS: There were 101 associations of interest for 61 drugs. Sixty-six associations were judged to have involved substantial confounding. We found evidence that of the remaining 35, the following associations may not be due to chance: sulindac with gallbladder cancer and leukemia, hyoscyamine with nonHodgkin lymphoma, nortriptyline with esophageal and hepatic cancer, oxazepam with lung cancer, both fluoxetine and paroxetine with testicular cancer, hydrochlorothiazide with renal and lip cancer, and nifedipine with lip cancer. CONCLUSIONS: These preliminary findings suggest that further studies are indicated regarding sulindac, hyoscyamine, nortriptyline, oxazepam, fluoxetine, paroxetine, hydrochlorothiazide, and nifedipine.
OBJECTIVE: To screen commonly used prescription drugs for possible carcinogenic effects. METHODS: In a large health care program we identified 105 commonly used drugs, not previously screened. Recipients were followed for up to 12½ years for incident cancer. Nested case-control analyses of 55 cancer sites and all combined included up to ten matched controls per case, with lag of at least 2 years between drug dispensing and cancer. Positive associations entailed a relative risk of 1.50, with p ≤ 0.01 and higher risk for three or more, than for one prescription. Evaluation included further analyses, searches of the literature, and clinical judgment. RESULTS: There were 101 associations of interest for 61 drugs. Sixty-six associations were judged to have involved substantial confounding. We found evidence that of the remaining 35, the following associations may not be due to chance: sulindac with gallbladder cancer and leukemia, hyoscyamine with nonHodgkin lymphoma, nortriptyline with esophageal and hepatic cancer, oxazepam with lung cancer, both fluoxetine and paroxetine with testicular cancer, hydrochlorothiazide with renal and lip cancer, and nifedipine with lip cancer. CONCLUSIONS: These preliminary findings suggest that further studies are indicated regarding sulindac, hyoscyamine, nortriptyline, oxazepam, fluoxetine, paroxetine, hydrochlorothiazide, and nifedipine.
Authors: Gary D Friedman; E Dawn Flick; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel Journal: Pharmacoepidemiol Drug Saf Date: 2008-01 Impact factor: 2.890
Authors: A B Beiderbeck-Noll; M C J M Sturkenboom; P D van der Linden; R M C Herings; A Hofman; J W W Coebergh; H G M Leufkens; B H Ch Stricker Journal: Eur J Cancer Date: 2003-01 Impact factor: 9.162
Authors: Michael C Irizarry; David J Webb; Nada Boudiaf; John Logie; Laurel A Habel; Natalia Udaltsova; Gary D Friedman Journal: Pharmacoepidemiol Drug Saf Date: 2011-12-06 Impact factor: 2.890
Authors: Victoria Rotshild; Laurent Azoulay; Majd Zarifeh; Reem Masarwa; Bruria Hirsh-Raccah; Amichai Perlman; Mordechai Muszkat; Ilan Matok Journal: Drug Saf Date: 2018-06 Impact factor: 5.606
Authors: Jiu-Qiang Xiong; Byong-Hun Jeon; Sanjay P Govindwar; Mayur B Kurade; Swapnil M Patil; Jung-Han Park; Ki-Hyun Kim Journal: Environ Sci Pollut Res Int Date: 2019-10-24 Impact factor: 4.223
Authors: Gary D Friedman; Joan Schwalbe; Ninah Achacoso; Maxwell V Meng; Candyce H Kroenke; Laurel A Habel Journal: Cancer Causes Control Date: 2013-11-26 Impact factor: 2.506